1
|
Kaewseekhao B, Sirichoat A, Roytrakul S, Yingchutrakul Y, Reechaipichitkul W, Faksri K. Serum proteomics analysis for differentiation among Mycobacterium tuberculosis infection categories. Tuberculosis (Edinb) 2023; 141:102366. [PMID: 37379738 DOI: 10.1016/j.tube.2023.102366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Revised: 05/28/2023] [Accepted: 06/20/2023] [Indexed: 06/30/2023]
Abstract
Inhalation of Mycobacterium tuberculosis (Mtb) bacilli can lead to a range of TB categories including early clearance (EC), latent TB infection (LTBI) and active TB (ATB). There are few biomarkers available to differentiate among these TB categories: effective new biomarkers are badly needed. Here, we analyzed the serum proteins from 26 ATB cases, 20 LTBI cases, 34 EC cases and 38 healthy controls (HC) using label-free LC-MS/MS. The results were analyzed using MaxQuant software and matched to three different bacterial proteomics databases, including Mtb, Mycobacterium spp. and normal lung flora. PCA of protein candidates using the three proteomics databases revealed 44.5% differentiation power to differentiate among four TB categories. There were 289 proteins that showed potential for distinguishing between each pair of groups among TB categories. There were 50 candidate protein markers specifically found in ATB and LTBI but not in HC and EC groups. Decision trees using the top five candidate biomarkers (A0A1A2RWZ9, A0A1A3FMY8, A0A1A3KIY2, A0A5C7MJH5 and A0A1X0XYR3) had 92.31% accuracy to differentiate among TB categories and the accuracy was increased to 100% when using 10 candidate biomarkers. Our study shows that proteins expressed from Mycobacterium spp. have the potential to be used to differentiate among TB categories.
Collapse
Affiliation(s)
- Benjawan Kaewseekhao
- Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; Research and Diagnostic Center for Emerging Infectious Diseases (RCEID), Khon Kaen University, Khon Kaen, Thailand
| | - Auttawit Sirichoat
- Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; Research and Diagnostic Center for Emerging Infectious Diseases (RCEID), Khon Kaen University, Khon Kaen, Thailand
| | - Sittiruk Roytrakul
- National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani, Thailand
| | - Yodying Yingchutrakul
- National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani, Thailand
| | - Wipa Reechaipichitkul
- Research and Diagnostic Center for Emerging Infectious Diseases (RCEID), Khon Kaen University, Khon Kaen, Thailand; Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
| | - Kiatichai Faksri
- Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; Research and Diagnostic Center for Emerging Infectious Diseases (RCEID), Khon Kaen University, Khon Kaen, Thailand.
| |
Collapse
|
2
|
Guo H, An J, Li S, Ding B, Zhang Z, Shu W, Shang Y, Wang Y, Cheng K, Wang Y, Xue Z, Ren W, Pan J, Luo T, Pang Y. Transmission and resistome of extremely drug-resistant tuberculosis in Beijing, China: A retrospective population-based epidemiological study. J Infect Public Health 2023; 16:1193-1200. [PMID: 37271100 DOI: 10.1016/j.jiph.2023.05.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Revised: 01/10/2023] [Accepted: 05/17/2023] [Indexed: 06/06/2023] Open
Abstract
BACKGROUND In this study, we utilized whole genome sequencing (WGS) of clinical extremely drug-resistant tuberculosis (EDR-TB) strains collected during 2014-2020 in Beijing to detect clustered strains. METHODS A retrospective cohort study was conducted by inclusion of EDR-TB patients with positive cultures in Beijing between 2014 and 2020. RESULTS A total of 95 EDR-TB patients were included in our analysis. Up on the WGS based genotyping, 94 (94/95, 98.9%) out of 95 were identified as lineage 2 (East Asia). The pairwise genomic distance analysis identified 7 clusters, ranging in size from 2 to 5 isolates. The clustering rate of EDR-TB was 21.1%; while no patients had significantly higher odds of clustering. All isolates harbor rpoB RRDR mutations that confer RIF resistance and katG or inhA promoter mutations that confer INH resistance. Of 95 EDR-TB isolates, a total of 15 mutation types were recorded in the transcriptional regulator mmpR5. In vitro susceptibility testing results revealed that 14 (14/15, 93.3%) out of 15 mutation types were resistant to CFZ; whereas only 3 (3/15, 20.0%) showed resistance to BDQ. Interestingly, 12 isolates harbored mutations within rrl locus, whereas only mutations at positions 2294 and 2296 conferred CLA resistance. Favorable outcomes of EDR-TB patients were positively associated with more effective drugs in the regimes. CONCLUSION WGS data demonstrate limited transmission of EDR-TB in this metropolis city. WGS-based drug susceptibility predictions will bring benefits to EDR-TB patients to formulate optimal therapeutic regimens.
Collapse
Affiliation(s)
- Haiping Guo
- Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Postal No 9, Beiguan Street, Tongzhou District, Beijing 101149, PR China
| | - Jun An
- Medical Record Department, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, PR China
| | - Shanshan Li
- Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Postal No 9, Beiguan Street, Tongzhou District, Beijing 101149, PR China
| | - Beichuan Ding
- Clinical Center on TB, Beijing Institute of Tuberculosis Control, Beijing 101149, PR China
| | - Zhiguo Zhang
- Clinical laboratory, Beijing Changping District Tuberculosis Prevention and Control Institute, Beijing 101149, PR China
| | - Wei Shu
- Clinical Center on TB, Beijing Chest Hospital, Capital Medical University/ Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, PR China
| | - Yuanyuan Shang
- Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Postal No 9, Beiguan Street, Tongzhou District, Beijing 101149, PR China
| | - Yi Wang
- Laboratory of Infection and Immunity, Department of Pathogen Biology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Postal No 17, People's South Road, Chengdu 610041, PR China
| | - Ken Cheng
- Laboratory of Infection and Immunity, Department of Pathogen Biology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Postal No 17, People's South Road, Chengdu 610041, PR China
| | - Yufeng Wang
- Department of Laboratory Quality Control, Innovation Alliance on Tuberculosis Diagnosis and Treatment (Beijing), Beijing 101149, PR China
| | - Zhongtan Xue
- Department of Laboratory Quality Control, Innovation Alliance on Tuberculosis Diagnosis and Treatment (Beijing), Beijing 101149, PR China
| | - Weicong Ren
- Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Postal No 9, Beiguan Street, Tongzhou District, Beijing 101149, PR China
| | - Junhua Pan
- Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Postal No 9, Beiguan Street, Tongzhou District, Beijing 101149, PR China.
| | - Tao Luo
- Laboratory of Infection and Immunity, Department of Pathogen Biology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Postal No 17, People's South Road, Chengdu 610041, PR China.
| | - Yu Pang
- Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Postal No 9, Beiguan Street, Tongzhou District, Beijing 101149, PR China.
| |
Collapse
|
3
|
Li Z. The Value of GeneXpert MTB/RIF for Detection in Tuberculosis: A Bibliometrics-Based Analysis and Review. JOURNAL OF ANALYTICAL METHODS IN CHEMISTRY 2022; 2022:2915018. [PMID: 36284547 PMCID: PMC9588380 DOI: 10.1155/2022/2915018] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Revised: 09/26/2022] [Accepted: 10/01/2022] [Indexed: 06/16/2023]
Abstract
With the continuous development of medical science and technology, especially with the advent of the era of precision diagnosis and treatment, molecular biology detection technology is widely valued and applied as an aid to early diagnosis of tuberculosis. The GeneXpert Mycobacterium tuberculosis Branching (MTB) technology is a suite of semi-nested real-time fluorescent quantitative PCR in vitro diagnostic technologies developed by Cepheid Inc. It targets the rifampicin resistance gene, rpoB, and can detect both MTB and resistance to rifampicin within 2 h. This review analyzed the papers related to GeneXpert using bibliometric software CiteSpace and Bibliometrix. A total of 151 articles were analyzed, spanning from 2011 to 2021. This bibliometrics-based review summarizes the history of the development of GeneXpert in tuberculosis diagnosis and its current status. Contributions of different countries to the topic, journal analysis, key paper analysis, and clustering of keywords were used to analyze this topic.
Collapse
Affiliation(s)
- Zhiyi Li
- Laboratory Medicine, Nanan Hospital, Nanan, Quanzhou 362300, Fujian, China
| |
Collapse
|
4
|
Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013. Microbiol Spectr 2021; 9:e0040921. [PMID: 34851179 PMCID: PMC8635133 DOI: 10.1128/spectrum.00409-21] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
We designed this study to determine the trend of moxifloxacin resistance among multidrug-resistant tuberculosis (MDR-TB) patients from 2007 to 2013 in China to inform the composition of multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment regimens. We assessed moxifloxacin resistance among MDR-TB isolates collected in national drug resistance surveys in 2007 and 2013 that included 3,634 smear-positive and 7,206 culture-positive pulmonary tuberculosis patients, respectively. Moxifloxacin susceptibility was examined by a Mycobacterium growth indicator tube (MGIT) 960 for the 2007 isolates, and by the minimum inhibitory concentration (MIC) method for the 2013 isolates, at both breakpoints 0.5 and 2.0 μg/mL. Risk factors were explored through multivariable log-binominal regression analysis. Mutations in gyrA and gyrB for part of the isolates were also studied through sequencing. Of 401 MDR strains isolated in 2007, moxifiloxacin resistance could be determined for 319 (79.6%): 41 (12.9%) and 10 (3.1%) were resistant at 0.5 and 2.0 μg/mL, respectively. Of 365 MDR strains isolated in 2013, 338 (92.6%) could be analyzed: 140 (41.4%) and 79 (23.4%) were resistant at 0.5 and 2.0 μg/mL. For patients in 2007, no characteristics were significantly associated with moxifloxacin resistance. For patients in 2013, patients aged ≥60 years (adjusted prevalence ratio [aPR], 1.46; 95% confidence interval [CI], 1.10 to 1.93) were more likely to have resistance at 0.5 μg/mL, whereas those residing in eastern China compared to those in central China had an increased risk of resistance at both 0.5 (aPR, 1.85; 95% CI, 1.38 to 2.48) and 2.0 μg/mL (aPR, 2.14; 95% CI, 1.35 to 3.40). Sequencing results were obtained for 245 and 266 MDR-TB isolates in 2007 and 2013, respectively. In total, 34 of 38 (89.5%) and 89 of 104 (85.6%) of 2007 and 2013 moxifloxacin-resistant (0.5 μg/mL) MDR-TB strains had mutations in the gyrA and gyrB gene, respectively. Asp94Gly was the most common mutation among 2007 (11 of 38, 28.9%) and 2013 isolates (24 of 104, 23.1%) and conferred high-level moxifloxacin resistance. Moxifloxacin resistance among MDR-TB patients in China increased from modest to high from 2007 to 2013. Moxifloxacin should be used carefully as a potentially effective drug for composing MDR/RR-TB regimens especially for elderly patients in China. Individual susceptibility testing especially rapid molecular-based assays should be conducted to confirm the susceptibility to moxifloxacin. IMPORTANCE China is one of the high-burden countries for multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB). Moxifloxacin is one of the critical antituberculosis drugs for MDR/RR-TB treatment. Susceptibility to moxifloxacin is therefore very important to compose effective regimens and to provide protection against development of resistance of companion drugs such as bedaquiline and linezolid. There are, however, no nationally representative data on moxifloxacin resistance among MDR/RR-TB cases in China. Therefore, we assessed the resistance prevalence for moxifloxacin among MDR-TB strains isolated in national drug resistance surveys in 2007 and 2013 that covered 72 sites around the country. We demonstrate that the prevalence of moxifloxacin resistance in MDR-TB isolates increased from modest to high, which should prompt the national tuberculosis program to use moxifloxacin cautiously in second-line regimens to treat MDR/RR-TB unless susceptibility can be laboratory-confirmed.
Collapse
|
5
|
Fan J, An J, Shu W, Huo F, Li S, Wang F, Qin S, Pang Y. Epidemiology of skeletal tuberculosis in Beijing, China: a 10-year retrospective analysis of data. Eur J Clin Microbiol Infect Dis 2020; 39:2019-2025. [DOI: 10.1007/s10096-020-03924-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Accepted: 05/01/2020] [Indexed: 12/19/2022]
|
6
|
Tabriz NS, Skak K, Kassayeva LT, Omarkulov BK, Grigolashvili MA. Efficacy of the Xpert MTB/RIF Assay in Multidrug-Resistant Tuberculosis. Microb Drug Resist 2020; 26:997-1004. [PMID: 32181685 DOI: 10.1089/mdr.2019.0326] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background: Half a million new cases of multidrug-resistant tuberculosis (MDR-TB) are registered annually, and therefore, the issue of the development of new fast and reliable methods for diagnosis of tuberculosis (TB) remains urgent in modern phthisiology. Aims: The aim of this study was to investigate the effects of the Xpert MTB/RIF molecular genetic method on the diagnosis, clinical and radiological features, and efficacy of treatment of MDR-TB. Materials and Methods: Patients with MDR-TB were divided into two groups. The first (study) group included patients (n = 412) in whom a mutation in the gene responsible for the presence of Mycobacterium tuberculosis (MTB) and resistance to rifampicin were detected using the Xpert MTB/RIF assay. The second group consisted of patients (n = 540) in whom TB was diagnosed using bacterioscopy and multidrug resistance was detected using inoculation on dense and liquid culture media. The results of bacterioscopic, bacteriological, molecular genetic, clinical studies and the efficacy of the treatment of 952 patients with MDR pulmonary TB were studied. The result of GeneXpert MTB/RIF was compared with the results of sputum bacterioscopy and culture methods on a dense Levenshtein-Jensen nutrient medium and on a liquid nutrient medium in a BACTEC 960 automated microbiological system. Results: The "Successful treatment" outcome ("cured" and "treatment completed") prevailed among patients who underwent timely diagnosis of MDR-TB using the Xpert MTB/RIF assay and reached 73.8%. In the second group of patients, it was 49.3% (p = 0.000). Conclusion: Timely diagnosis of MDR-TB using the Xpert MTB/RIF assay increased the efficacy of anti-TB chemotherapy.
Collapse
Affiliation(s)
- Nurlan S Tabriz
- Department of Phthisiology, Karaganda State Medical University, Karaganda, Republic of Kazakhstan
| | - Kuliya Skak
- Department of Phthisiology, Karaganda State Medical University, Karaganda, Republic of Kazakhstan
| | - Lazzat T Kassayeva
- Department of Therapeutic Disciplines, South Kazakhstan Medical Academy, Shymkent, Republic of Kazakhstan
| | - Bauyrzhan K Omarkulov
- Department of Clinical Work and Employment of Graduates and Karaganda State Medical University, Karaganda, Republic of Kazakhstan
| | - Marina A Grigolashvili
- Department of Neurosurgery and Neurology, Karaganda State Medical University, Karaganda, Republic of Kazakhstan
| |
Collapse
|
7
|
Kaewseekhao B, Nuntawong N, Eiamchai P, Roytrakul S, Reechaipichitkul W, Faksri K. Diagnosis of active tuberculosis and latent tuberculosis infection based on Raman spectroscopy and surface-enhanced Raman spectroscopy. Tuberculosis (Edinb) 2020; 121:101916. [PMID: 32279876 DOI: 10.1016/j.tube.2020.101916] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2019] [Revised: 02/15/2020] [Accepted: 02/17/2020] [Indexed: 12/17/2022]
Abstract
Current tools for screening LTBI are limited due to the long turnaround time required, cross-reactivity of tuberculin skin test to BCG vaccine and the high cost of interferon gamma release assay (IGRA) tests. We evaluated Raman spectroscopy (RS) for serum-protein fingerprinting from 26 active TB (ATB) cases, 20 LTBI cases, 34 early clearance (EC; TB-exposed persons with undetected infection) and 38 healthy controls (HC). RS at 532 nm using candidate peaks provided 92.31% sensitivity and 90.0% to distinguish ATB from LTBI, 84.62% sensitivity and 89.47% specificity to distinguish ATB from HC and 87.10% sensitivity and 85.0% specificity to distinguish LTBI from EC. RS at 532 nm with the random forest model provided 86.84% sensitivity and 65.0% specificity to distinguish LTBI from HC and 94.74% sensitivity and 87.10% specificity to distinguish EC from HC. Using preliminary sample sets (n = 5 for each TB-infection category), surface-enhanced Raman spectroscopy (SERS) showed high potential diagnostic performance, distinguishing very clearly among all TB-infection categories with 100% sensitivity and specificity. With lower cost, shorter turnaround time and performance comparable to that of IGRAs, our study demonstrated RS and SERS to have high potential for ATB and LTBI diagnosis.
Collapse
Affiliation(s)
- Benjawan Kaewseekhao
- Department of Microbiology and Research and Diagnostic Center for Emerging Infectious Diseases, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
| | - Noppadon Nuntawong
- National Electronics and Computer Technology Center (NECTEC), National Science and Technology Development Agency (NSTDA), Rama VI Rd., Pathumthani, Thailand
| | - Pitak Eiamchai
- National Electronics and Computer Technology Center (NECTEC), National Science and Technology Development Agency (NSTDA), Rama VI Rd., Pathumthani, Thailand
| | - Sittiruk Roytrakul
- National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Rama VI Rd., Pathumthani, Thailand
| | - Wipa Reechaipichitkul
- Department of Medicine and Diagnostic Center for Emerging Infectious Diseases, Faculty of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
| | - Kiatichai Faksri
- Department of Microbiology and Research and Diagnostic Center for Emerging Infectious Diseases, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
| |
Collapse
|
8
|
Prevalence and risk factors of pulmonary nontuberculous mycobacterial infections in the Zhejiang Province of China. Epidemiol Infect 2019; 147:e269. [PMID: 31506134 PMCID: PMC6807301 DOI: 10.1017/s0950268819001626] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Risk factors and prevalence of pulmonary nontuberculous mycobacterial (NTM) diseases were retrospectively evaluated in 1208 suspected pulmonary TB patients seeking care at the Affiliated Hospital of Hangzhou Normal University between July 2018 and December 2018. Further analysis of 390 culture-positive cases demonstrated that 358 (358/390, 91.8%) were infected with Mycobacterium tuberculosis (MTB), 24 (24/390, 6.2%) with NTM and eight (8/390, 2.0%) with both MTB and NTM. M. intracellulare was the most prevalent NTM isolated (16/24, 66.7%), followed by M. abscessus (3/24), M. kansasii (2/24), M. avium (1/24), M. szulgai (1/24) and M. fortuitum (1/24). The difference between NTM and TB case rates for the ⩾65-year-old age group significantly exceeded the difference for the reference group (patients aged 25-44 years) (OR (95% CI): 4.63 (1.03-20.90)). Pulmonary NTM diseases incidence positively correlated with prior TB history (OR (95% CI): 12.92 (3.24-31.82)). Moreover, pulmonary NTM patients were significantly more likely to exhibit underlying bronchiectasis than pulmonary TB patients (OR (95% CI): 18.89 (7.54-47.88)). In conclusion, approximately one-tenth of culture-positive suspected pulmonary TB patients are infected with NTM (most frequently M. intracellulare) in Zhejiang Province, China. The elderly and those with bronchiectasis or a history of TB are at the greatest risk of contracting pulmonary NTM disease.
Collapse
|